We’re excited to announce that we’ve closed our £50 million ($67M) Series B financing round to advance our pipeline of #microbiome-based therapeutics built on our world-leading platform, advanced #bioinformatic capabilities, and microbial genomes database microbiotica.com/microbiotic…

We are delighted to see the excellent article about our #microbiome magic in @DrugTargetRev! 🔗Read all about it here: drugtargetreview.com/article… #biotech #lifesciences ⬇️Microbiotica: transforming medicine with microbiome magic

Microbiotica's VP Pre-Clinical Development Adam Wilkinson and VP Clinical Development Claire Birrell are presenting a poster about MB310, our Live Bacterial Therapeutic (#LBT) for the treatment of ulcerative colitis, at the #IBDInnovate conference in New York City on April 26.

Pleased to collaborate with MSD to conduct a phase 1b trial to evaluate the safety and clinical activity of MB097 and KEYTRUDA® combination therapy in #melanoma patients #Microbiome #ClinicalTrial Read more here: microbiotica.com/microbiotic…

Microbiotica's SVP Research, Mat Robinson, is attending #AACR2023 Annual Meeting in Orlando, FL from Apr 14-19. The global event for cancer researchers and professionals to share cutting-edge advancements in cancer science and medicine. #CancerResearch #Microbiome

Don't miss our Director of Cell Biology, Ghaith Bakdash, discussing "Clinic-First Design Of A Live Bacterial Therapeutic (MB310) For #UlcerativeColitis" and joining a panel on "Utilising The Microbiome For Autoimmune & Cancer Care" at #Immuno2023 in London on March 28. #LBT

Our CEO Tim Sharpington is presenting at the Microbiome #innovation showcase during the UK Microbiome One Health Conference in Glasgow on March 24th at 9:55 am! Join us to learn and discuss everything about the #microbiome #OneHealth.

Discover our groundbreaking work in microbiome-based therapeutics and biomarkers for high medical need areas. Check out the new case study from @sangerinstitute here: bit.ly/3liATfp #Microbiome #Genomics #Therapeutics #LBT

Microbiotica’s CEO, Tim Sharpington, will be part of a panel discussion at the 7th #MicrobiomeMovement conference in London, 1 February at 4:30 PM. Tim will be exploring how Microbiotica closed a £50M Series B financing round in March 2022. See you there! #Microbiome

With 2022 coming to an end, we look forward to advancing our understanding of the role of the #microbiome and building our pipeline. Read about the impact of the microbiome on #cancer therapy by Mike Romanos and Matthew Robinson in Mednous: lnkd.in/efECR5u2 #LBP

Our VP Preclinical Development Adam Wilkinson will discuss #microbiome-based #therapies as a new modality and the potential of our microbiome #platform at the 19th Annual #bioProcessUK in #Edinburgh. Join his talk at 11:30am Nov 16. #BIA #BioPharma bioprocessuk.org/

We’re looking forward to the 7th Microbiome Connect USA, 16-17 Nov, with talks covering #biotech, #drugdevelopment, #microbiome and beyond, bringing together #pharma, #investors and industry players to share knowledge, collaborate and address challenges. kisacoresearch.com/events/mi…

Our new article on unlocking the #microbiome as a multi-therapeutic modality is live on @bpdealmakers. Read the full article to explore our lead program and its potential in microbiome-based #therapies: nature.com/articles/d43747-0… #Partnering #Cancer

Microbiotica's COO Tim Sharpington and CBO Matthew Roe will be attending this year's BIO-Europe in Leipzig, Germany, 24-26 October. We are excited to return to the industry’s largest gathering of #biopharma professionals in Europe. See you there! #BIOEurope #Microbiome

Watch Ghaith Bakdash, Director Cell Biology discuss our work on #microbiome signatures and the newly developed bacterial consortium, highlighting applications of MB097 as potential #therapeutic for #cancer in this interview with @MicrobiomePost microbiomepost.com/how-micro… #LBT

Microbiotica’s Mat Robinson, VP Translational Biology, will be presenting “Precision #Microbiome Profiling Enables Discovery Of A Clinically-Defined Consortium Of Bacteria With Potent Anti-Tumour Activity” at Immuno UK on 29 September at 11:10 AM: oxfordglobal.co.uk/immuno-se…

Today we join cancer researchers around the world to celebrate #WorldCancerResearchDay! We are proud to be part of the work being done in the field of #CancerResearch and thank all our dedicated scientists who are contributing to our research. #Cancer #Microbiome #LBT

Listen to Microbiotica’s co-founder and CSO Trevor Lawley at the 22nd Cambridge Immunology Forum discussing ‘Cancer at the interface of #immunity, #metabolism and #microbiota’ at Queen’s College, @Cambridge_Uni on 23 September. Find out more here: med.cam.ac.uk/cif2022/

We are honoured to have been shortlisted in the category “Private Financing Deal of the Year” for @Pharma_Intell #ScripAwards. Thanks to all our investors @TencentGlobal #FlerieInvest @BPatientCap @SeventureP @cic_vc @IPGroupplc #Awards #Biotech